Sunday, October 16, 2022 from 2:15 PM to 3:45 PM PDT at Imperial Ballroom A
Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-22-160-L01-P
Activity Type: A Knowledge-Based Activity
In this session, clinical experts will provide targeted updates on advancements in nephrology that may improve patient outcomes across the spectrum of patient care. From a chronic disease standpoint, pharmacologic agents, such as the SGLT-2 inhibitors and finerenone, with demonstrated benefit in the delay of CKD progression will be discussed. Additionally, significant advancements in predictive models of acute kidney injury and drug dosing utilizing cystatin C will be discussed.
 | Moderator: Katherine Cho, Pharm.D., BCACP
Clinical Assistant Professor – Ambulatory Care
Temple University School of Pharmacy
Philadelphia, Pennsylvania |
Learning Objectives
1. Summarize recent scientific literature supporting use of pharmacologic agents to improve macro- and microvascular outcomes in patients with kidney disease.
2. Describe mechanism of action, initiation, adverse effects, and monitoring of novel nephroprotective drugs in patients with kidney disease.
3. Discuss strategies to facilitate multidisciplinary care, communication, and care transitions for patients with kidney disease on novel nephroprotective drugs.
4. Review current literature on predictive models of acute kidney injury (AKI).
5. Discuss disease-state specific literature demonstrating predictive models of acute kidney injury (AKI).
6. Summarize evidence supporting the use of cystatin C in assessing estimated glomerular filtration rate (eGFR) for medication dosing in comparison to standard renal estimates.